Stakeholder Opinions: Ovarian Cancer

Approaching the era of molecular targeted therapy

Product Code DAT19569
Publication Date July 2010
Publisher Datamonitor
Product Type Report
Pages 93
ISBN Number not applicable
Change currency
PDF £2,405.00 €2,896 $3,803 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Stakeholder Opinions: Ovarian Cancer

Approaching the era of molecular targeted therapy

Introduction

Despite advances in the management of the disease, outcomes remain poor for patients with advanced epithelial ovarian cancer. The high level of unmet need, coupled with the large size of the patient population, is driving extensive R&D interest in this indication. The anticipated incorporation of molecular targeted therapies into treatment is expected to improve patient outcomes in the future.

Scope of this research

  • Ovarian cancer overview, including disease definition, epidemiology, discussion of unmet needs, and market potential
  • Current treatment options for ovarian cancer and ongoing controversies
  • Examination of the late-phase ovarian cancer pipeline, including drug profiles of late-stage agents
  • Stakeholder opinions based on qualitative interviews with key opinion leaders from the US and EU

Research and analysis highlights

Ovarian cancer is the leading cause of death from gynecological malignancies in the Western world. This is because the majority of epithelial ovarian cancer patients present with advanced disease at diagnosis, where treatment has a palliative rather than curative intent.

While first-line platinum-based chemotherapy can result in high response rates of over 70-80%, the majority of patients will advanced epithelial ovarian cancer will eventually relapse with incurable disease. As such, there is a need for novel first-line therapies to improve survival rates.

R&D interest in ovarian cancer is high. There are currently 85 drugs in the pipeline, which is dominated by molecular targeted therapies (42%) and cytotoxic therapies (33%). Competition for the approval of the first molecular targeted therapy in ovarian cancer is fierce.

Key reasons to purchase this research

  • Estimate the number of treatable patients and identify unmet needs for future drug development opportunities
  • Understand the current treatment of the disease, as well as opportunities and threats in the ovarian cancer market
  • Analyze the current ovarian cancer pipeline and the potential of late-stage drugs

Contents

  • OVERVIEW
    • Catalyst
    • Summary
  • EXECUTIVE SUMMARY
    • Scope of the analysis
    • Datamonitor insight into the ovarian cancer market
    • Related reports
    • Upcoming reports
  • PATIENT POTENTIAL
    • Key findings
    • Definition
      • Epithelial tumors
      • Germ cell tumors
      • Sex cord-stromal tumors
      • A successful screening test for ovarian cancer has not been developed
      • Ovarian cancer is a surgically staged malignancy
    • Epidemiology
      • The incidence of ovarian cancer in the seven major markets is forecast to reach nearly 63,000 cases by 2019
      • The highest ovarian cancer rates prevail in Northern European countries
    • Current treatment options
      • Most early-stage patients are treated with surgery and chemotherapy
    • Unmet need
      • More effective agents are required for the treatment of advanced disease
      • An effective screening test could significantly improve patient survival
      • R&D efforts should be directed towards molecular targeted therapies
      • Less invasive surgical approaches should be explored for early-stage patients
  • MARKET POTENTIAL
    • Key findings
    • Current market overview
    • Opportunities and threats
      • Opportunities
      • Threats
  • PIPELINE ANALYSIS
    • Key findings
    • Ovarian cancer pipeline overview
    • Ovarian cancer late-phase pipeline
      • Avastin (bevacizumab; Genentech/Roche/Chugai)
      • Karenitecin (cositecan; BNP-1350; BioNumerik)
      • Opaxio (paclitaxel poliglumex; Cell Therapeutics/Novartis)
      • Paclical (micellar paclitaxel formulation; Oasmia)
      • Tarceva (erlotinib; Genentech/Roche/Chugai/OSI)
      • Vargatef (intedanib; BIBF-1120; Boehringer Ingelheim)
      • Votrient (pazopanib; GlaxoSmithKline)
      • Farletuzumab (MORAb-003; Morphotek/Eisai)
      • Abagovomab (Menarini/Cell Control Biomedical)
  • BIBLIOGRAPHY
    • Journals
    • Websites
    • Datamonitor reports
  • APPENDIX
    • Contributing experts
    • Report methodology
  • TABLES
    • Table: Staging of ovarian cancer using the International Federation of Gynecology and Obstetrics (FIGO) and American Joint Committee on Cancer (AJCC) classification
    • Table: Crude incidence rates of ovarian cancer per 100,000 population in the seven major pharmaceutical markets, 2002
    • Table: Forecast incidence of ovarian cancer in the seven major pharmaceutical markets, 2002–2019
    • Table: Top 5 countries with the highest crude incidence rates of ovarian cancer, 2002
    • Table: Survival results for randomized Phase III trials comparing cisplatin-paclitaxel with carboplatin-paclitaxel in advanced ovarian cancer
    • Table: Survival and selected toxicity results for randomized Phase III trial comparing docetaxel-carboplatin versus paclitaxel-carboplatin in ovarian cancer
    • Table: Randomized trials in platinum-sensitive ovarian cancer
    • Table: Selected clinical trial results for Yondelis presented at the American Society of Clinical Oncology (ASCO) meeting, June 2010
    • Table: Drugs approved by the US Food & Drug Administration (FDA) for the treatment of ovarian cancer
    • Table: Pipeline agents in Phase III development for ovarian cancer, 2010
    • Table: Pipeline agents in Phase II development for ovarian cancer, 2010
    • Table: Pipeline agents in Phase I development for ovarian cancer, 2010
    • Table: Avastin – drug profile, 2010
    • Table: Ongoing Phase III clinical trials for Avastin in ovarian cancer, 2010
    • Table: Selected Phase II trials of Avastin in ovarian cancer
    • Table: Karenitecin – drug profile, 2010
    • Table: Ongoing clinical trials for Karenitecin in ovarian cancer, 2010
    • Table: Phase II results for Karenitecin in the third-line treatment of recurrent or persistent platinum-resistant epithelial ovarian or primary peritoneal cancer
    • Table: Opaxio – drug profile, 2010
    • Table: Ongoing clinical trials for Opaxio in ovarian cancer, 2010
    • Table: Paclical – drug profile, 2010
    • Table: Ongoing clinical trials for Paclical in ovarian cancer, 2010
    • Table: Tarceva – drug profile, 2010
    • Table: Ongoing clinical trials for Tarceva in ovarian cancer, 2010
    • Table: Clinical trial results for Tarceva maintenance therapy in ovarian cancer
    • Table: Vargatef – drug profile, 2010
    • Table: Ongoing clinical trials for Vargatef in ovarian cancer, 2010
    • Table: Phase II results for Vargatef as maintenance therapy in advanced ovarian cancer
    • Table: Votrient – drug profile, 2010
    • Table: Ongoing clinical trials for Votrient in ovarian cancer, 2010
    • Table: Phase II results for Votrient maintenance therapy in epithelial ovarian, fallopian tube or primary peritoneal cancer patients with a rising CA 125 level following first- or second-line therapy
    • Table: Farletuzumab – drug profile, 2010
    • Table: Ongoing clinical trials for farletuzumab in ovarian cancer, 2010
    • Table: Results of a Phase II study evaluating farletuzumab in platinum-sensitive ovarian cancer at first relapse, 2010
    • Table: Abagovomab – drug profile, 2010
    • Table: Ongoing clinical trials for abagovomab in ovarian cancer, 2010
    • Table: Phase I/II results for abagovomab as maintenance therapy in recurrent ovarian cancer
  • FIGURES
    • Figure: Cellular origin of the three main types of ovarian cancer
    • Figure: Stage distribution and corresponding 5-year survival rate for ovarian cancer in the US, 1999–2005
    • Figure: Forecast incidence and mortality of ovarian cancer in 2010 and 2019 across the seven major pharmaceutical markets
    • Figure: Forecast incidence of ovarian cancer in Brazil, Russia, India, and China, 2010 and 2019
    • Figure: Key unmet needs in ovarian cancer, 2010
    • Figure: Number of drugs in development for ovarian cancer by phase of development, 2010
    • Figure: Ovarian cancer pipeline by type of therapy, 2010
    • Figure: Ovarian cancer late-phase pipeline by type of therapy, 2010
    • Figure: Avastin – SWOT analysis in ovarian cancer, 2010
    • Figure: Karenitecin – SWOT analysis in ovarian cancer, 2010
    • Figure: Opaxio – SWOT analysis in ovarian cancer, 2010
    • Figure: Paclical – SWOT analysis in ovarian cancer, 2010
    • Figure: Tarceva – SWOT analysis in ovarian cancer, 2010
    • Figure: Vargatef – SWOT analysis in ovarian cancer, 2010
    • Figure: Phase II trial design for Votrient maintenance therapy in epithelial ovarian, fallopian tube or primary peritoneal cancer patients with a rising CA 125 level following first- or second-line therapy
    • Figure: Votrient – SWOT analysis in ovarian cancer, 2010
    • Figure: Design of a Phase II study evaluating farletuzumab in platinum-sensitive ovarian cancer at first relapse
    • Figure: Farletuzumab – SWOT analysis in ovarian cancer, 2010
    • Figure: Abagovomab – SWOT analysis in ovarian cancer, 2010